CCL2 and melanoma: However, according to a report published by the same group [89], the aforementioned oral regimen of BSE has been implicated in decreasing pro-inflammatory cytokines human interferon-inducible protein 10 (IP-10), monocyte chemoattractant protein 1 (MCP-1), monokine induced by gamma (MIG), and macrophage inflammatory protein 1β (MIP-1β), along with decreased IFN-γ and increased tumor suppressor decorin in skin nevi of patients with a history of melanoma.